Trial Profile
A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Etravirine (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 04 Aug 2019 Status changed from recruiting to completed.
- 17 May 2011 New trial record